|
Mr. Hale has been Chairman since February 2004 and has served as a member of the Santarus board of directors since June 2000. From October 2000 to May 2006 Mr. Hale served as President and Chief Executive Officer of CancerVax Corporation a biotechnology company specializing in the treatment and control of cancer. From December 2000 to May 2006 Mr. Hale was also a director of CancerVax. In May 2006 CancerVax merged with Micromet AG to form Micromet Inc. a biopharmaceutical company of which Mr. Hale is Chairman. Prior to joining CancerVax Corporation Mr. Hale served as President and Chief Executive Officer and a director of Women First HealthCare Inc. a specialty healthcare company from January 1998 to May 2000. From May 1987 to October 1997 he served as Chairman President and Chief Executive Officer of Gensia Sicor Inc. (acquired by Teva Pharmaceutical Industries Limited) formerly Gensia Inc. a specialty pharmaceutical company and from February 1987 to September 1994 served as Chairman of Viagene Inc. a biotechnology company. Mr. Hale joined Hybritech Incorporated a biotechnology company in 1982 and served as President and a Director until May 1987. Mr. Hale has served as a director of Metabasis Therapeutics Inc. since April 1997 and as Chairman of Somaxon Pharmaceuticals Inc.'s board of directors since August 2003. Mr. Hale holds a B.A. in biology and chemistry from Jacksonville State University.
| 